We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+11.01%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$3.4B
AUM Growth
+$210M
Cap. Flow
+$20.2M
Cap. Flow %
0.59%
Top 10 Hldgs %
33.65%
Holding
105
New
22
Increased
13
Reduced
16
Closed
20

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$107M
2
CRBU icon
Caribou Biosciences
CRBU
+$100M
3
CYTK icon
Cytokinetics
CYTK
+$43.4M
4
SOPH icon
SOPHiA GENETICS
SOPH
+$35.6M
5
AZN icon
AstraZeneca
AZN
+$33.6M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$166M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$68.5M
3
MYOV
Myovant Sciences Ltd.
MYOV
+$43.5M
4
BIIB icon
Biogen
BIIB
+$37.8M
5
BAX icon
Baxter International
BAX
+$36.9M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BFLY icon
51
Butterfly Network
BFLY
$2.34B
$19.1M 0.56%
1,828,311
– –
MOH icon
52
Molina Healthcare
MOH
$10.1B
$19M 0.56%
70,088
– –
ISEE
53
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18.5M 0.54%
+1,138,112
New +$12.4M
STVN icon
54
Stevanato
STVN
$5.52B
$13.9M 0.41%
+549,002
New +$12.9M
SGHT icon
55
Sight Sciences
SGHT
$289M
$11M 0.32%
+483,538
New +$15.9M
AVIR icon
56
Atea Pharmaceuticals
AVIR
$387M
$10.6M 0.31%
+302,532
New +$8.39M
GH icon
57
Guardant Health
GH
$22B
$10.6M 0.31%
84,455
-289,676
-77% -$34.4M
ZLAB icon
58
Zai Lab
ZLAB
$2.06B
$10.5M 0.31%
99,375
– –
DVAX
59
CALL
DELISTED
Dynavax Technologies
DVAX
$10M 0.29%
+521,800
New +$6.93M
PRDS
60
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$9.95M 0.29%
1,000,000
– –
DXCM icon
61
DexCom
DXCM
$31.4B
$9.58M 0.28%
+70,040
New +$8.83M
PMVP icon
62
PMV Pharmaceuticals
PMVP
$62.9M
$8.59M 0.25%
288,334
– –
PRAX icon
63
Praxis Precision Medicines
PRAX
$8.68B
$8.42M 0.25%
30,358
– –
HUM icon
64
CALL
Humana
HUM
$43.6B
$8.17M 0.24%
+21,000
New +$8.91M
HOWL icon
65
Werewolf Therapeutics
HOWL
$20.1M
$6.86M 0.2%
400,000
– –
LAB icon
66
Standard BioTools
LAB
$312M
$6.46M 0.19%
980,505
– –
LFST icon
67
Lifestance Health
LFST
$3.98B
$6.43M 0.19%
443,595
– –
KNTE
68
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$6.08M 0.18%
264,293
– –
LUNG icon
69
Pulmonx
LUNG
$82.4M
$4.91M 0.14%
136,576
– –
DCPH
70
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$4.87M 0.14%
+143,297
New +$4.57M
BIIB icon
71
Biogen
BIIB
$30.9B
$4.78M 0.14%
16,900
-115,372
-87% -$37.8M
CERT icon
72
Certara
CERT
$1.26B
$4.73M 0.14%
143,028
– –
BLSA
73
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$4.64M 0.14%
464,103
– –
JYAC
74
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$4.54M 0.13%
464,103
– –
VECT
75
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$4.21M 0.12%
544,706
-66,368
-11% -$569K
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return

PFM Health Sciences's Q3 2021 Portfolio in Review

As of Q3 2021, PFM Health Sciences held 105 positions worth $3.4B, up 6.6% from $3.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

PFM Health Sciences's Q3 2021 filing shows 22 new, 13 increased, 16 reduced and 20 closed positions. Its largest new stake was Erasca: 5,191,405 shares worth $98.2M. The largest sale was Alexion Pharmaceuticals, an estimated $166M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 92% a quarter earlier, followed by Financials.

  • PFM Health Sciences's largest Q3 2021 buy was Erasca: 5,191,405 shares worth $98.2M.
  • PFM Health Sciences added most to Cytokinetics in Q3 2021, an estimated $43.4M increase.
  • PFM Health Sciences's biggest Q3 2021 reduction was Biogen, cutting an estimated $37.8M.
  • PFM Health Sciences fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $166M.
  • PFM Health Sciences's ten largest holdings make up 34% of its $3.4B portfolio in Q3 2021.
  • PFM Health Sciences opened 22 new positions and closed 20 in Q3 2021.
  • PFM Health Sciences's portfolio value rose 6.6% quarter-over-quarter to $3.4B.

Based on PFM Health Sciences's 13F filing for Q3 2021, filed 15 Nov 2021.